PTJ
CAPR icon

Paul Tudor Jones’s Capricor Therapeutics CAPR Stock Holding History

Paul Tudor Jones’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,600
Closed -$306K – 3659
2025
Q4 		$306K Buy
+10,600
New +$138K ﹤0.01% 3038

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Paul Tudor Jones's CAPR Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in Capricor Therapeutics (CAPR) in Q2 2026: 15,816 shares worth $381K. The stake represents ﹤0.01% of the portfolio and ranks #2990 among its holdings.

169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Paul Tudor Jones held 15,816 shares of Capricor Therapeutics worth $381K as of Q2 2026.
  • Capricor Therapeutics was a new Paul Tudor Jones position in Q2 2026.
  • Capricor Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2990 holding.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.